^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HY004
i
Other names: HY004, HY 004, Anti-CD19-anti-CD22 CAR-T cell therapy, autologous CD19-CD22 CAR-T cells, HY-004
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Juventas Cell Therapy
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
8ms
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (clinicaltrials.gov)
P1/2, N=50, Not yet recruiting, Juventas Cell Therapy Ltd. | Initiation date: Oct 2023 --> Aug 2024
Trial initiation date
|
IL6 (Interleukin 6)
|
CD19 expression
|
cyclophosphamide • fludarabine IV • HY004
8ms
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=80, Not yet recruiting, Juventas Cell Therapy Ltd. | Initiation date: Oct 2023 --> Aug 2024
Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CD22 (CD22 Molecule)
|
CD19 positive • BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • HY004
over1year
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=80, Not yet recruiting, Juventas Cell Therapy Ltd.
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
CD19 positive • BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • HY004
over2years
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
P1, N=2, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital | Trial primary completion date: Dec 2021 --> Dec 2023
Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
HY004
Share via
